New oral antithrombotics: a need for laboratory monitoring. For

See also Bounameaux H, Reber G. New oral antithrombotics: a need for laboratory monitoring. Against. This issue, pp 627–30.

[1]  J. Douketis,et al.  Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. , 2006, JAMA.

[2]  J. Atherton,et al.  Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes. , 2005, British journal of clinical pharmacology.

[3]  J. Mattson,et al.  The heparin anti-Xa therapeutic range: are we there yet? , 2002, Chest.

[4]  A. Maestre,et al.  Venous thromboembolism in patients with renal insufficiency: findings from the RIETE Registry. , 2006, The American journal of medicine.

[5]  H. Büller,et al.  A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial , 2005, Journal of thrombosis and haemostasis : JTH.

[6]  D Thomas,et al.  Anti-Xa Activity Relates to Survival and Efficacy in Unselected Acute Coronary Syndrome Patients Treated With Enoxaparin , 2004, Circulation.

[7]  J. Hirsh,et al.  Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study. , 2000, Archives of internal medicine.

[8]  G. Montalescot,et al.  Enoxaparin in unstable angina patients with renal failure. , 2001, International journal of cardiology.

[9]  Panos Deloukas,et al.  The largest prospective warfarin-treated cohort supports genetic forecasting. , 2009, Blood.

[10]  J. Douketis,et al.  A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. , 2003, The New England journal of medicine.

[11]  Lain,et al.  A COMPARISON OF ENOXAPARIN WITH PLACEBO FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS , 2000 .

[12]  M. Alhenc-Gelas,et al.  Adjusted Versus Fixed Doses of the Low-Molecular-Weight Heparin Fragmin in the Treatment of Deep Vein Thrombosis , 1994, Thrombosis and Haemostasis.

[13]  F. Dentali,et al.  Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal Insufficiency , 2006, Annals of Internal Medicine.

[14]  G. Palareti,et al.  Oral Anticoagulant Therapy Control: Evidence that INR Expression Improves the Inter-Laboratory Comparability of Results - The Bologna Oral Anticoagulant Control Exercise , 1987, Thrombosis and Haemostasis.

[15]  S. Frostick,et al.  Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial , 2007, Journal of thrombosis and haemostasis : JTH.

[16]  E. Antman,et al.  Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction. , 2003, British journal of clinical pharmacology.

[17]  S. Urien,et al.  Dosing Strategy in Patients with Renal Failure Receiving Enoxaparin for the Treatment of non‐ST‐segment Elevation Acute Coronary Syndrome , 2005, Clinical pharmacology and therapeutics.

[18]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[19]  M. Gent,et al.  Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. , 2003, The New England journal of medicine.

[20]  B. Eriksson,et al.  Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. , 2006, British journal of clinical pharmacology.

[21]  S. Pauker,et al.  Effect of laboratory variation in the prothrombin-time ratio on the results of oral anticoagulant therapy. , 1993, The New England journal of medicine.

[22]  S. Yusuf,et al.  Influence of Renal Function on the Efficacy and Safety of Fondaparinux Relative to Enoxaparin in NonST-Segment Elevation Acute Coronary Syndromes , 2007, Annals of Internal Medicine.

[23]  J. Stangier.  Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate , 2008, Clinical pharmacokinetics.

[24]  P. Mismetti,et al.  Rivaroxaban : données pharmaco-cliniques , 2008 .

[25]  M. Prins,et al.  Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times. , 1999, Archives of internal medicine.

[26]  D. Mottier,et al.  Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function , 2007, Thrombosis and Haemostasis.

[27]  Piotr Pruszczyk,et al.  Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism , 2008 .

[28]  A. Turpie,et al.  A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. , 1999, The New England journal of medicine.

[29]  D. Singer,et al.  An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. , 1996, The New England journal of medicine.

[30]  S. Frostick,et al.  Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial , 2007, The Lancet.

[31]  D A Taberner,et al.  Effect of international sensitivity index (ISI) of thromboplastins on precision of international normalised ratios (INR) , 1989, Journal of clinical pathology.

[32]  P. Mismetti,et al.  Dabigatran : données pharmaco-cliniques , 2009 .

[33]  G. Raskob,et al.  Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. , 2009, The Journal of arthroplasty.

[34]  M Gent,et al.  Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. , 2003, The New England journal of medicine.

[35]  Bengt I Eriksson,et al.  Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement , 2008, Thrombosis and Haemostasis.

[36]  G. Raskob,et al.  Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. , 1997, Archives of internal medicine.